These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

248 related items for PubMed ID: 23999432

  • 1. ErbB3 downregulation enhances luminal breast tumor response to antiestrogens.
    Morrison MM, Hutchinson K, Williams MM, Stanford JC, Balko JM, Young C, Kuba MG, Sánchez V, Williams AJ, Hicks DJ, Arteaga CL, Prat A, Perou CM, Earp HS, Massarweh S, Cook RS.
    J Clin Invest; 2013 Oct; 123(10):4329-43. PubMed ID: 23999432
    [Abstract] [Full Text] [Related]

  • 2. Decreased LRIG1 in fulvestrant-treated luminal breast cancer cells permits ErbB3 upregulation and increased growth.
    Morrison MM, Williams MM, Vaught DB, Hicks D, Lim J, McKernan C, Aurisicchio L, Ciliberto G, Simion C, Sweeney C, Cook RS.
    Oncogene; 2016 Mar 03; 35(9):1143-52. PubMed ID: 26148232
    [Abstract] [Full Text] [Related]

  • 3. Activation of ErbB3, EGFR and Erk is essential for growth of human breast cancer cell lines with acquired resistance to fulvestrant.
    Frogne T, Benjaminsen RV, Sonne-Hansen K, Sorensen BS, Nexo E, Laenkholm AV, Rasmussen LM, Riese DJ, de Cremoux P, Stenvang J, Lykkesfeldt AE.
    Breast Cancer Res Treat; 2009 Mar 03; 114(2):263-75. PubMed ID: 18409071
    [Abstract] [Full Text] [Related]

  • 4. Fulvestrant-induced expression of ErbB3 and ErbB4 receptors sensitizes oestrogen receptor-positive breast cancer cells to heregulin β1.
    Hutcheson IR, Goddard L, Barrow D, McClelland RA, Francies HE, Knowlden JM, Nicholson RI, Gee JM.
    Breast Cancer Res; 2011 Mar 11; 13(2):R29. PubMed ID: 21396094
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Therapeutic targeting of erbB3 with MM-121/SAR256212 enhances antitumor activity of paclitaxel against erbB2-overexpressing breast cancer.
    Wang S, Huang J, Lyu H, Cai B, Yang X, Li F, Tan J, Edgerton SM, Thor AD, Lee CK, Liu B.
    Breast Cancer Res; 2013 Mar 11; 15(5):R101. PubMed ID: 24168763
    [Abstract] [Full Text] [Related]

  • 7. Seribantumab, an Anti-ERBB3 Antibody, Delays the Onset of Resistance and Restores Sensitivity to Letrozole in an Estrogen Receptor-Positive Breast Cancer Model.
    Curley MD, Sabnis GJ, Wille L, Adiwijaya BS, Garcia G, Moyo V, Kazi AA, Brodie A, MacBeath G.
    Mol Cancer Ther; 2015 Nov 11; 14(11):2642-52. PubMed ID: 26310543
    [Abstract] [Full Text] [Related]

  • 8. Novel anti-ErbB3 monoclonal antibodies show therapeutic efficacy in xenografted and spontaneous mouse tumors.
    Aurisicchio L, Marra E, Luberto L, Carlomosti F, De Vitis C, Noto A, Gunes Z, Roscilli G, Mesiti G, Mancini R, Alimandi M, Ciliberto G.
    J Cell Physiol; 2012 Oct 11; 227(10):3381-8. PubMed ID: 22213458
    [Abstract] [Full Text] [Related]

  • 9. Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways.
    Ghayad SE, Vendrell JA, Ben Larbi S, Dumontet C, Bieche I, Cohen PA.
    Int J Cancer; 2010 Jan 15; 126(2):545-62. PubMed ID: 19609946
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Fulvestrant regulates epidermal growth factor (EGF) family ligands to activate EGF receptor (EGFR) signaling in breast cancer cells.
    Zhang X, Diaz MR, Yee D.
    Breast Cancer Res Treat; 2013 Jun 15; 139(2):351-60. PubMed ID: 23686416
    [Abstract] [Full Text] [Related]

  • 12. AKT Antagonist AZD5363 Influences Estrogen Receptor Function in Endocrine-Resistant Breast Cancer and Synergizes with Fulvestrant (ICI182780) In Vivo.
    Ribas R, Pancholi S, Guest SK, Marangoni E, Gao Q, Thuleau A, Simigdala N, Polanska UM, Campbell H, Rani A, Liccardi G, Johnston S, Davies BR, Dowsett M, Martin LA.
    Mol Cancer Ther; 2015 Sep 15; 14(9):2035-48. PubMed ID: 26116361
    [Abstract] [Full Text] [Related]

  • 13. Conditional loss of ErbB3 delays mammary gland hyperplasia induced by mutant PIK3CA without affecting mammary tumor latency, gene expression, or signaling.
    Young CD, Pfefferle AD, Owens P, Kuba MG, Rexer BN, Balko JM, Sánchez V, Cheng H, Perou CM, Zhao JJ, Cook RS, Arteaga CL.
    Cancer Res; 2013 Jul 01; 73(13):4075-85. PubMed ID: 23633485
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.